• Publications
  • Influence
Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
BACKGROUND The cardiovascular effects of adding once‐weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS We randomly assigned patients with type 2Expand
  • 734
  • 45
  • PDF
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
IMPORTANCE Studies in experimental and human heart failure suggest that phosphodiesterase-5 inhibitors may enhance cardiovascular function and thus exercise capacity in heart failure with preservedExpand
  • 785
  • 28
  • PDF
Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure.
CONTEXT Readmission after hospitalization for heart failure is common. Early outpatient follow-up after hospitalization has been proposed as a means of reducing readmission rates. However, there areExpand
  • 844
  • 27
  • PDF
Diuretic strategies in patients with acute decompensated heart failure.
BACKGROUND Loop diuretics are an essential component of therapy for patients with acute decompensated heart failure, but there are few prospective data to guide their use. METHODS In a prospective,Expand
  • 749
  • 26
  • PDF
Somatosensory discrimination based on cortical microstimulation
The sensation of flutter is produced when mechanical vibrations in the range of 5–50 Hz are applied to the skin. A flutter stimulus activates neurons in the primary somatosensory cortex (S1) thatExpand
  • 401
  • 26
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
BACKGROUND Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutideExpand
  • 453
  • 24
  • PDF
Ultrafiltration in decompensated heart failure with cardiorenal syndrome.
BACKGROUND Ultrafiltration is an alternative strategy to diuretic therapy for the treatment of patients with acute decompensated heart failure. Little is known about the efficacy and safety ofExpand
  • 609
  • 19
  • PDF
Incidence and Prevalence of Atrial Fibrillation and Associated Mortality Among Medicare Beneficiaries: 1993–2007
Background— Atrial fibrillation (AF) is a common and costly problem among older persons. The frequency of AF increases with age, but representative national data about incidence and prevalence areExpand
  • 356
  • 19
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.
BACKGROUND Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. METHODS Patients who wereExpand
  • 261
  • 18
  • PDF
Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
IMPORTANCE The benefits of intravenous tissue plasminogen activator (tPA) in patients with acute ischemic stroke (AIS) are time dependent and guidelines recommend a door-to-needle (DTN) time of 60Expand
  • 364
  • 15
  • PDF